Kenvue Inc. (NYSE:KVUE) Announces $0.20 Quarterly Dividend

Kenvue Inc. (NYSE:KVUEGet Free Report) declared a quarterly dividend on Thursday, January 25th, Zacks reports. Investors of record on Wednesday, February 14th will be given a dividend of 0.20 per share on Wednesday, February 28th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.12%. The ex-dividend date is Tuesday, February 13th.

Kenvue has a payout ratio of 59.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Kenvue to earn $1.31 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 61.1%.

Kenvue Stock Up 0.5 %

Shares of Kenvue stock opened at $19.43 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.78 and a current ratio of 1.14. The stock’s 50-day simple moving average is $20.96 and its 200-day simple moving average is $21.03. Kenvue has a 52 week low of $17.82 and a 52 week high of $27.80.

Kenvue (NYSE:KVUEGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a return on equity of 14.83% and a net margin of 9.87%. Kenvue’s revenue was down 2.7% compared to the same quarter last year. As a group, research analysts predict that Kenvue will post 1.19 EPS for the current year.

Institutional Trading of Kenvue

Several large investors have recently added to or reduced their stakes in the company. Citigroup Inc. purchased a new position in shares of Kenvue during the 2nd quarter valued at about $57,000. Fairfield Bush & CO. purchased a new stake in Kenvue during the second quarter worth $66,000. PNC Financial Services Group Inc. acquired a new stake in Kenvue during the second quarter valued at $73,000. Tower Research Capital LLC TRC acquired a new position in shares of Kenvue in the second quarter worth about $121,000. Finally, Osaic Holdings Inc. purchased a new stake in shares of Kenvue during the 2nd quarter worth about $144,000. Hedge funds and other institutional investors own 11.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on KVUE. Piper Sandler assumed coverage on shares of Kenvue in a report on Friday, November 17th. They set a “neutral” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday. UBS Group lifted their price objective on Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 19th. Finally, Royal Bank of Canada cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Moderate Buy” and a consensus target price of $25.92.

Check Out Our Latest Stock Analysis on KVUE

Kenvue Company Profile

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.

Recommended Stories

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.